Psychosis in Children and Adolescents

Overview & Epidemiology - Spotting Shadows Early

Psychosis in C&A: severe mental disorders, reality distortion. Rare; devastating developmental impact.

• Epidemiology:
  • Childhood-Onset Schizophrenia (COS; <13 yrs): Extremely rare (~1/30,000).
  • Adolescent-Onset (AOS; 13-18 yrs): Incidence ↑ sharply; overall psychosis prevalence ~0.5-1%.
• Impact: Profound on development; poorer prognosis with very early onset. High comorbidity.
• Red Flags (C&A vs. Adults):
  • Onset: Often insidious.
  • Hallucinations: Visual/tactile more common initially; simpler content.
  • Delusions: Less complex, concrete, often child-themed.
  • Thought/Speech: Disorganization harder to discern from immaturity/language issues.
  • Negative Symptoms: Prominent; may mimic depression/developmental issues.
  • Developmental context crucial.

⭐ Very early onset schizophrenia (VEOS; onset <13 years) carries a worse prognosis and stronger genetic loading than later-onset forms.

Etiology & Differentials - Roots & Look-Alikes

Etiology:

• Genetic: Strong heritability; family Hx (psychosis/SCZ); 22q11.2 deletion.
• Neurobiological: Dopamine (DA) dysregulation; Glutamate, GABA, 5-HT roles; Neurodevelopmental insults (e.g., pruning defects).
• Environmental: Prenatal (infections), perinatal (hypoxia), childhood trauma, urbanicity.
• Substance Use: Cannabis (esp. adolescent, high-THC), stimulants.

Key Differential Diagnoses:

Clinical Features & Diagnosis - Clues & Confirmation

• Often insidious onset; look for developmental regression or decline in functioning.

• Hallucinations: Auditory most common; visual/tactile more frequent than in adults, often simpler.

• Delusions: Less systematized, more concrete (e.g., persecutory, somatic).

• Negative symptoms: Social withdrawal, apathy, alogia can be prominent.

• Mood symptoms (anxiety, depression, irritability) & cognitive deficits common.

• Thorough history: Child, parents, school; family history of psychosis vital.

• Developmentally-adapted Mental Status Examination (MSE).

• Exclude organic causes:

  • Substance use (especially cannabis).
  • Medical: Epilepsy, autoimmune encephalitis, infections, metabolic disorders.
  • Medications.

• Key Investigations: Blood tests, urine drug screen, EEG, neuroimaging (MRI preferred).

• Apply DSM-5/ICD-11 criteria.

⭐ Very Early Onset Psychosis (VEOS) is psychosis onset before age 13; Early Onset Psychosis (EOS) before 18. VEOS often has poorer prognosis.

Management & Prognosis - Healing Pathways

• Multimodal Treatment: Essential for optimal outcomes.
  • Pharmacotherapy: Second-generation antipsychotics (SGAs) e.g., risperidone, aripiprazole, are first-line. Start low, titrate slow.
    • Monitor closely: Metabolic effects (weight gain, dyslipidemia), EPS, hyperprolactinemia.
  • Psychosocial Interventions: Cognitive Behavioral Therapy for psychosis (CBTp), family therapy & psychoeducation, social skills training.
  • Early Intervention Services (EIS): Comprehensive, phase-specific care; critical for improving long-term trajectory.
• Prognosis Factors:
  • Better: Short Duration of Untreated Psychosis (DUP), acute onset, good premorbid functioning, strong family support, affective symptoms.
  • Worse: Long DUP, insidious onset, poor premorbid function, substance abuse, prominent negative symptoms, high expressed emotion in family.

  ⭐ Shorter Duration of Untreated Psychosis (DUP) is a key modifiable factor strongly predicting better functional and symptomatic outcomes.

• Outcomes: Variable; early, sustained, and comprehensive treatment significantly improves prognosis.

High‑Yield Points - ⚡ Biggest Takeaways

• Early-Onset Schizophrenia (EOS) <18 yrs; Very Early-Onset (VEOS) <13 yrs, linked to poorer prognosis & cognitive deficits.
• Auditory hallucinations most common; visual hallucinations & thought disorder more frequent than in adults.
• Key differentials: mood disorders with psychosis, Autism Spectrum Disorder (ASD), substance-induced psychosis.
• Second-generation antipsychotics (SGAs) (e.g., risperidone) are first-line; monitor metabolic side effects (weight gain, dyslipidemia).
• Comprehensive treatment requires pharmacotherapy plus psychosocial interventions (family therapy, CBTp).